Last reviewed · How we verify
Thymosin-α1
Thymosin-α1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activating innate and adaptive immunity.
Thymosin-α1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activating innate and adaptive immunity. Used for Cancer immunotherapy (phase 3 development), Viral infections and immune enhancement.
At a glance
| Generic name | Thymosin-α1 |
|---|---|
| Also known as | Zadaxin |
| Sponsor | Sun Yat-sen University |
| Drug class | Immunomodulatory peptide |
| Modality | Small molecule |
| Therapeutic area | Immunology / Oncology |
| Phase | Phase 3 |
Mechanism of action
Thymosin-α1 is a naturally occurring 28-amino acid peptide derived from the thymus gland that acts as an immunomodulator. It enhances T-cell differentiation and maturation, increases IL-2 and interferon-gamma production, and promotes both innate and adaptive immune responses. The peptide is thought to work through pattern recognition receptors and may enhance antitumor and antiviral immunity.
Approved indications
- Cancer immunotherapy (phase 3 development)
- Viral infections and immune enhancement
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) (NA)
- The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC (PHASE2)
- Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) (NA)
- Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC (NA)
- Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder (EARLY_PHASE1)
- Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (NA)
- Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer (PHASE2)
- Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymosin-α1 CI brief — competitive landscape report
- Thymosin-α1 updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI